Search

ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

December 10, 2018
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

September 07, 2018
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept.

September 05, 2018
ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

Press release

LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

November 14, 2017
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10

Press release

… of transformative RNA therapies for severe genetic rare diseases, today announced the publication in the … RNA therapy could potentially be used to treat early stage disease, which is enabled by the broad distribution of …

April 13, 2021
ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s

July 21, 2020
ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct.

October 15, 2019
ProQR Announces Presentations at the OTS Annual Meeting

Press release

LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

September 24, 2018
ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen

Press release

… of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will host an … and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the …

July 13, 2020
ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids

Press release

LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

August 01, 2018